Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Affinergy Signs Exclusive Development & License Agreement with Synthes.


RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. -- Affinergy, Inc., a Duke University spinout spin·out  
n.
An instance of spinning out: a motorist who was injured in a spinout. 
 with a proprietary site-specific biological delivery system, announced that it has entered into a multi-year development & license agreement with Synthes. Affinergy will work exclusively with Synthes on multiple product applications across the Spine, Trauma and Craniomaxillofacial markets.

"Synthes built its leadership position in the orthopedics market by continually providing innovative products," said Peyton Anderson, Affinergy's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Affinergy is very excited by the potential of these development programs to improve patient outcomes while better serving the surgeons' clinical practices. The market leading position of Synthes is an excellent platform to leverage the full potential of Affinergy's technology."

Hansjorg Wyss, Synthes Chairman and CEO, added "Synthes is very excited about the collaboration with Affinergy on this long-term biomaterials development program."

About Affinergy, Inc.

Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to adhere to
verb 1. follow, keep, maintain, respect, observe, be true, fulfil, obey, heed, keep to, abide by, be loyal, mind, be constant, be faithful

2.
 proteins, drugs, cells, and biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer.  surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com.

About Synthes

Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton The human skeleton consists of both fused and individual bones supported and supplemented by ligaments, tendons, muscles and cartilage. Fused bones include those of the pelvis and the cranium. Osteocytes are present in the bone matrix.  and its soft tissues. For more information, visit www.synthes.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 11, 2006
Words:247
Previous Article:USBX Advises Red Hawk Industries in Its Pending Sale to Strategic Buyer United Technologies Corporation.
Next Article:Pemco World Air Services Announces Agreement with International Lease and Finance Corporation to Convert B-737-300 Aircraft.
Topics:



Related Articles
Licensing TV Programs to the Internet: A Business Model.
CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
The University of Nebraska-Lincoln (UNL) and Monsanto Co. sign an exclusive licensing agreement to develop crops tolerant to the broadleaf herbicide...
BIOVITRIM/SANTHERA SIGN PACT FOR DEVELOPING DPP-IV.
Kyorin Pharmaceutical, Novartis AG Enter into Licensing Agreement for Immunosuppressant KRP-203.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles